Exploratory Analyses of Circulating Neoplastic-Immune Hybrid Cells as Prognostic Biomarkers in Advanced Intrahepatic Cholangiocarcinoma

• Published in: International journal of molecular sciences Vol. 25; no. 17; p. 9198
• Main Authors: Patel, Ranish K, Parappilly, Michael S, Walker, Brett S, Heussner, Robert T, Fung, Alice, Chang, Young Hwan, Kardosh, Adel, Lopez, Charles D, Mayo, Skye C, Wong, Melissa H
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.09.2024
• Subjects: Aged; Antigens; Bile Duct Neoplasms - blood; Bile Duct Neoplasms - diagnosis; Bile Duct Neoplasms - metabolism; Bile Duct Neoplasms - pathology; Biomarkers; Biomarkers, Tumor - blood; cancer biomarker; Cancer therapies; Cholangiocarcinoma; Cholangiocarcinoma - blood; Cholangiocarcinoma - pathology; circulating hybrid cells; circulating tumor cells; Female; Humans; intrahepatic cholangiocarcinoma; Keratins - metabolism; Leukocyte Common Antigens - metabolism; Liver; Male; Medical prognosis; Middle Aged; Morphology; Neoplastic Cells, Circulating - metabolism; Neoplastic Cells, Circulating - pathology; Patients; Prognosis; Surveillance; Tomography; circulating hybrid cells; cancer biomarker; circulating tumor cells; intrahepatic cholangiocarcinoma
• ISSN: 1661-6596; 1422-0067; 1422-0067
• DOI: 10.3390/ijms25179198

Existing clinical biomarkers do not reliably predict treatment response or disease progression in patients with advanced intrahepatic cholangiocarcinoma (ICC). Circulating neoplastic-immune hybrid cells (CHCs) have great promise as a blood-based biomarker for patients with advanced ICC. Peripheral blood specimens were longitudinally collected from patients with advanced ICC enrolled in the HELIX-1 phase II clinical trial (NCT04251715). CHCs were identified by co-expression of pan-cytokeratin (CK) and CD45, and levels were correlated to patient clinical disease course. Unsupervised machine learning was then performed to extract their morphological features to compare them across disease courses. Five patients were included in this study, with a median of nine specimens collected per patient. A median of 13.5 CHCs per 50,000 peripheral blood mononuclear cells were identified at baseline, and levels decreased to zero following the initiation of treatment in all patients. Counts remained undetectable in three patients who demonstrated end-of-trial clinical treatment response and conversely increased in two patients with evidence of therapeutic resistance. In the post-trial surveillance period, interval counts increased prior to or at the time of clinical progression in three patients and remain undetectable in one patient with continued long-term disease stability. Using our machine learning platform, treatment-resistant CHCs exhibited upregulation of CK and downregulation of CD45 relative to treatment-responsive CHCs. CHCs represent a promising blood-based biomarker to supplement traditional radiographic and biochemical measures.